PRS42 ASTHMA DISEASE BURDEN, EVIDENTIARY REQUIREMENTS, AND FORMULARY CONSIDERATIONS AMONG MANAGED CARE AND EMPLOYER DECISION MAKERS REGARDING INHALED CORTICOSTEROIDS (ICS)  by O'Day, K et al.
asthma patients that reported occurrences of at least one asthma
attack in twelve months. Multiple logistic regression was used to
determine what factors are associated with the risk of absent
controller drug therapy despite the frequent use of quick relief
drugs, i.e., zero use of controllers in 12 months despite the use of
3 or more quick relief canisters in three months. RESULTS: A
total of 1164 patients reported at least one asthma attack in past
12 months. Among these patients, 434 (37%) reported no use of
controller drugs despite the frequent use of quick relief canisters.
The patients that did not have peak ﬂow meter at home were
more likely to report no use of controller drugs despite the
frequent use of quick relief drugs (OR = 1.93; 95% CI:1.92,
1.93). Health insurance (OR = 1.44; 95% CI: 1.43, 1.45) and
prescription drug beneﬁts (OR = 1.21; 95% CI: 1.21, 1.21) also
increased the risk of absent controller drug therapy. CONCLU-
SION: Having peak ﬂow meter increased the likelihood of con-
troller drug use indicating the usefulness of peak ﬂow meter in
asthma treatment and management. Health insurance and pre-
scription drug beneﬁt improved the likelihood of using controller
drugs because of improved access. In order to improve the con-
troller drug utilization amongst asthma patients, attention
should be focused on patients lacking health insurance, prescrip-
tion drug beneﬁts and peak ﬂow meters.
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OBJECTIVE: Rational treatment of bronchial asthma is a
serious problem in developing countries mainly because of access
to medicines. This paper reports the availability and price of two
inhalers in different states of India. METHODS: The data col-
lected for essential medicines at ﬁve sites utilizing a standardized
methodology on medicine prices and availability was used to
collate data for secondary analysis. The surveys were conducted
in public (20–60) and private (20–60) facilities. Anti-asthma
medicines, beclomethasone (50mg/dose) and salbutamol (0.1 mg/
dose) inhalers represented both as innovator brand (IB) and
generic equivalent, were included in the analysis. Medicine prices
were expressed as median price ratio (MPR) to an international
reference price. The surveys were conducted in four states,
Haryana, Karnataka, Maharashtra, Rajasthan and Chennai,
capital TamilNadu, state. Surveys were conducted from
October–December 2004 except Rajasthan survey (April-June
2003). RESULTS: Public sector: Availability—Generic version of
both the inhalers was found only in the Rajasthan state. Avail-
ability of beclomethasone inhaler was 25% and 30% for salb-
utamol. Procurement price –Beclomethasone inhaler was 0.74
and salbutamol inhaler was 0.56 times the international refer-
ence price. Private sector: Availability—Beclomethasone inhaler
was available as innovator brand (55%) and generic version
(90%) in Chennai. In other states only generic version was
available, in the range of 10% to 65%. Salbutamol inhaler
was available in all states and in both the versions, availability
ranging between 20%–95% as innovator brand and 83 -100%
as generic equivalent. Price—MPR for generic beclomethasone
was in the range of 0.87–1.49 at all sites, IB was available in
Chennai and the MPR was 1.08. MPRs for IB and generic
salbutamol range between 0.86–1.12 and 0.82–0.96 respec-
tively. CONCLUSION: Policy interventions are required to
improve access of affordable essential asthma medicines. Asthma
needs to be recognized as a health priority chronic disease in
India.
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OBJECTIVE: To gather information from managed care orga-
nization (MCO) decision makers and employers about asthma
burden, evidentiary requirements, and product attributes that
may inﬂuence formulary decision making for an emerging once-
daily ICS asthma therapy. METHODS: Telephone interviews
were conducted among 10 MCO decision makers and 8
employers representing more than 51 million covered lives.
Research focused on asthma burden, disease management strat-
egies, and formulary decision making. Mean ratings on a scale
from 1 (no effect; not at all important) to 10 (very large effect;
very important). RESULTS: Both MCOs and employers recog-
nized the prevalence of asthma and challenges associated with
management, including patient compliance with ICS. MCOs
reported the economic impact of asthma was most notable in
terms of hospitalizations (7.3), emergency department visits
(7.2), and pharmaceutical costs (7.0). Employers identiﬁed
burden of illness with employee absenteeism (6.0), presenteeism
(5.3), workplace productivity (5.4), and employer health care
costs stemming from both employee asthma and dependent
children with asthma (5.3). ICS product efﬁcacy, safety, com-
pliance, and cost-effectiveness/value were the most important
product attributes driving formulary decision making among
MCOs. Both MCOs and employers had a favorable overall
opinion of the product (6.9 and 6.8, respectively) and felt that
compliance (8.4 and 8.9, respectively) would have a consider-
able impact on decision making. Majority of MCOs (7 of 10)
reported once-daily dosing to be the most important product
attribute (6.9). MCO interviewees emphasized that the product
will need to be priced competitively to secure favorable posi-
tioning in a crowded ICS market. Post-launch evidentiary
requirements may include the need for “real world” head-to-
head comparative effectiveness studies. CONCLUSION: Efﬁ-
cacy, safety, compliance, and cost are primary factors driving
formulary decision making when evaluating emerging ICS
asthma therapies in a crowded market. MCO and employer
organizations have similar priorities with respect to asthma
management and formulary decision making.
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OBJECTIVE: Recent estimates of cost of asthma among chil-
dren in the USA are not available. The objective of this study
was to estimate the incremental direct medical expenditures of
treating asthma among children in the USA. METHODS:
Retrospective analysis was conducted using the 2004 Medical
Expenditure Panel Survey (MEPS) data. Asthmatic children
(age < 18 years; n = 968) were identiﬁed as those with Interna-
tional Classiﬁcation of Diseases (ICD)-9 diagnosis codes for
asthma or those that had a self-report of having asthma in
2004. Separate regression models were developed for total
expenditures and expenditures for various categories of resource
use adjusting for age, gender, race, ethnicity, education, geo-
graphic region, insurance status and number of medications
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